title: Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
abstract: BACKGROUND
  The present study aimed to evaluate cardiometabolic risks [weight gain, blood lipid levels (total cholesterol and triglycerides), blood glucose levels, hemoglobin A1c (HbA1c) levels, and corrected QT interval (QTc) prolongation] associated with the use of blonanserin and perospirone versus other antipsychotics in the management of patients with schizophrenia.
  
  
  METHODS
  We conducted a systematic review and meta-analysis of patient data from randomized controlled trials comparing blonanserin or perospirone with other antipsychotics.
  
  
  RESULTS
  In total, 4 blonanserin studies (n = 1080) were identified [vs. risperidone (2 studies, n = 508); vs. haloperidol (2 studies, n = 572)]. Blonanserin produced less weight gain compared with risperidone (weighted mean difference = -0.86, 95% confidence intervals = -1.36 to -0.36, p = 0.0008; 2 studies, 480 patients). However, no significant differences were observed in blood lipid, glucose, and HbA1c levels or QTc prolongation between blonanserin and risperidone or haloperidol. For perospirone studies, 5 studies [562 adult patients with schizophrenia randomized to perospirone (n = 256), olanzapine (n = 20), quetiapine (n = 28), risperidone (n = 53), aripiprazole (n = 49), haloperidol (n = 75), or mosapramine (n = 81)] were identified. Perospirone did not differ from other antipsychotics with regard to weight gain and total cholesterol levels.
  
  
  CONCLUSIONS
  Our results suggest that blonanserin is associated with a lower of weight gain compared with other antipsychotics. Because the number of studies was small, additional controlled clinical trials with larger number of patients are indicated.
authors: Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
authors: Taro
authors: T
authors: Kishi
authors: Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
authors: Yuki
authors: Y
authors: Matsuda
authors: Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
authors: Nakao
authors: N
authors: Iwata
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001786:Blood Glucose / Q000187:drug effects; D004311:Double-Blind Method; D006442:Glycated Hemoglobin / Q000378:metabolism; D006321:Heart / Q000187:drug effects*; D006801:Humans; D054833:Isoindoles / Q000009:adverse effects* / Q000627:therapeutic use*; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use*; D015430:Weight Gain / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D054833:Isoindoles; D010879:Piperazines; D010880:Piperidines; D013844:Thiazoles; C517652:hemoglobin A1c protein, human; C079310:blonanserin; C065533:perospirone